Literature DB >> 34204149

Indications and Clinical Outcomes of Transoral Robotic Surgery and Free Flap Reconstruction.

Philippe Gorphe1, Stéphane Temam1, Antoine Moya-Plana1, Nicolas Leymarie2, Frédéric Kolb3, Apolline Bout-Roumazeilles2, Quentin Qassemyar4, Nadia Benmoussa1, Jean-François Honart2.   

Abstract

We reviewed the indications, peroperative feasibility, and postoperative clinical outcomes of our first 50 consecutive patients who underwent free flap reconstruction after TORS for complex pharyngeal defects at our institution. We analyzed indications according to previous radiotherapy, the size of the resection, and the transoral exposure of critical structures. We reviewed surgical data, postoperative complications, and functional outcomes comprising tracheostomy and alimentation management. Indications were upfront surgery (34%), a second primary surgery after radiotherapy (28%), or salvage surgery after chemoradiotherapy failure (38%). Localizations were the tongue base (44%), tonsillar fossa (28%), pharyngeal wall (22%), and soft palate (6%). T-classifications were T1 (6%), T2 (52%), T3 (20%), and T4 (22%). The mean length of the surgery was 574 min. Two patients were intraoperatively converted to a conventional approach at the beginning of the learning curve. In conclusion, TORS and free flap reconstruction in complex situations were associated with low rates of postoperative complications and satisfactory functional outcomes. They were, however, associated with a renewed learning curve.

Entities:  

Keywords:  free tissues flaps; oropharyngeal neoplasms; postoperative complications; quality of life; reconstructive surgical procedures; robotic surgery procedures

Year:  2021        PMID: 34204149     DOI: 10.3390/cancers13112831

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  1 in total

1.  Current perspectives on recurrent HPV-mediated oropharyngeal cancer.

Authors:  Theresa Guo; Stephen Y Kang; Ezra E W Cohen
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.